The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a recalibration of long-term outlooks in the biotechnology sector, Erste Group Bank analysts have lowered their FY2027 earnings per share estimate for Amgen to $23.58 from $23.62. The bank maintained its 'Hold' rating on the stock, signaling a neutral stance despite the company recently beating consensus estimates for both revenue and earnings. This revision suggests a cautious approach to the company's long-term growth trajectory.
This minor adjustment comes as Amgen navigates a competitive landscape; peer Gilead Sciences recently reported robust results driven by oncology sales, according to recent earnings filings. Per market data, large-cap biotech valuations have remained relatively stable as investors seek greater clarity on drug pipelines and the potential impact of evolving healthcare regulations on sector profitability.
Amgen (AMGN) shares stood at $371.58 at the close of July 16, 2026, having traded within a range of $357.74 to $372.14 during that session. Investors are now looking toward broader market catalysts following the Federal Reserve's Monetary Policy Report on July 10, which continues to influence sentiment regarding capital-intensive sectors like healthcare and biotechnology.